Discontinue immediately in case of signs suggesting allergic reactions (eg, angioedema, urticaria or skin rash); paradoxical bronchospasm. Do not swallow cap. Do not use to treat acute asthma symptoms, including acute episodes of bronchospasm. Do not abruptly stop treatment. Risk of hypokalaemia w/ β-agonists. Plasma glucose should be monitored more closely in diabetic patients upon treatment initiation. Rinse mouth or gargle w/ water w/o swallowing after inhalation to reduce the risk of oropharyngeal candida infection. Systemic effects (eg, Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in childn & adolescents, decrease in bone mineral density, cataracts, glaucoma, & psychological or behavioural effects) of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. Patients w/ CV disorders (CAD, acute MI, cardiac arrhythmias, HTN), convulsive disorders or thyrotoxicosis & who are unusually responsive to β2
-adrenergic agonists; known or suspected QT interval prolongation or who are being treated w/ medicinal products affecting the QT interval; type I or uncontrolled Type II DM; pulmonary TB or chronic or untreated infections; rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption; severe hepatic impairment. Pregnancy & lactation. Paed patients <12 yr.